Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Azusa, California 91702


Purpose:

Comfort is compared between two allergy drops


Criteria:

Inclusion Criteria: - Between the ages of 18 and over inclusive. - Males or females - Patient is in generally good & stable overall health. - Patient likely to comply with study guidelines & study visits. - Informed consent signed. - History of allergic conjunctivitis - Current symptoms of allergic conjunctivitis assessed by the investigator Exclusion Criteria: - Corneal refractive surgery or contact lens wear within 6 months of this study. - Current use of Restasis - Intra-ocular surgery within 6 months or ocular laser surgery within 6 months. - Pregnant or lactating women. - Ocular pathology (includes glaucoma and cataract), which could impact results and/or place patient at risk.


Study is Available At:


Original ID:

IIT-000256


NCT ID:

NCT01390961


Secondary ID:


Study Acronym:


Brief Title:

Comparison of Tolerability Between Two Allergy Drops


Official Title:

Comparison of Tolerability Between Two Allergy Drops


Overall Status:

Enrolling by invitation


Study Phase:

Phase 4


Genders:

Both


Minimum Age:

18 Months


Maximum Age:

N/A


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

Hom, Milton M., OD, FAAO


Oversight Authority:

United States: Institutional Review Board


Reasons Why Stopped:


Study Type:

Interventional


Study Design:

Allocation: Randomized, Endpoint Classification:


Number of Arms:

1


Number of Groups:

0


Total Enrollment:

48


Enrollment Type:

Anticipated


Study Dates

Start Date:August 2011
Completion Date:January 2012
Completion Type:Anticipated
Primary Completion Date:December 2011
Primary Completion Type:Anticipated
Verification Date:July 2011
Last Changed Date:July 7, 2011
First Received Date:July 7, 2011

Study Outcomes

Outcome Type:Primary Outcome
Measure:Tolerability
Time Frame:8 weeks
Safety Issues:False
Description:Tolerability measured by questionnaire Visual Analog scale 1 to 100

Study Interventions

Intervention Type:Drug
Name:alacaftadine and naphazoline HCl & pheniramine
Description:once a day
Other Name:Lastacaft

Study Arms

There are no available Study Arms

Study Agencies

Agency Class:Other
Agency Type:Lead Sponsor
Agency Name:Hom, Milton M., OD, FAAO
Agency Class:Industry
Agency Type:Collaborator
Agency Name:Allergan

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


This study is not currently recruiting Study Participants. The form below is not enabled.